🔹 Adj. EPS: $1.06 (Est. $0.92) 🟢; UP +6% YoY
🔹 Revenue: $5.00B (Est. $4.97B) 🟢; UP +3% YoY
FY25 Guidance (Raised):
🔹 Adj. EPS: $4.43–$4.63 (Prior: $3.90–$4.10) 🟢
🔹 Organic Revenue Growth: ~+3% (Prior: +2% to +3%)
🔹 Adj. EBIT Margin: 15.2%–15.4% (Prior: 14.2%–14.4%)
🔹 Adj. Tax Rate: 20%–21% (Prior: 21%–22%)
🔹 Free Cash Flow: ≥ $1.4B (Prior: ≥ $1.2B)
Q2 Segment Revenue (YoY):
🔹 Imaging: $2.20B, UP +2%;
🔹 Advanced Visualization: $1.29B
🔹 Patient Care Solutions: $778M, UP +1%
🔹 Pharma Diagnostics: $729M, UP +14%
Other Key Metrics:
🔹 Organic Revenue Growth: +2% YoY
🔹 Net Income: $486M (vs. $428M YoY)
🔹 Adj. EBIT: $729M (vs. $742M YoY)
🔹 Adj. EBIT Margin: 14.6% (vs. 15.3% YoY); -80 bps
🔹 Adj. Free Cash Flow: $94M (vs. $(119)M YoY); Free Cash Flow: $7M
🔹 Book-to-Bill: 1.07x
CEO Commentary:
🔸 “Solid orders and revenue across all segments; earnings strength reflects lean execution and tariff mitigation.” – CEO Peter Arduini
🔸 “Largest-ever order of Omni Legend PET systems; driving long-term value through precision care and AI innovation.”